查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1571448

製药市场的市场规模、份额和趋势分析报告：按产品、经济、适应症、地区和细分市场预测，2024-2030

Pharmerging Market Size, Share & Trends Analysis Report By Product (Pharmaceutical, Healthcare), By Economy (Tier-1, Tier-2), By Indication (Lifestyle Disease, Infectious Disease), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格
简介目录

医药市场的成长与趋势：

预计2030年全球医药市场规模将达2.8兆美元，2024年至2030年复合年增长率预计为2.6%。

由于老年人口的增加、慢性病造成的疾病负担的增加以及医疗保健支出的增加，预计该市场将会扩大。

根据联合国 (UN) 统计，2015 年 60 岁及以上人口估计为 9.01 亿。日益增长的老龄化人口将推动对高血脂症、高血压、失智症、痴呆症和郁血性心臟衰竭等慢性疾病更好的治疗选择的需求。根据德勤2011年进行的一项研究，老年人口几乎占医药市场的23.0-40.0%，占OTC医药市场的40.0-50.0%。推动医药市场的另一个因素是医疗支出的增加。

新兴国家慢性病负担的增加正在推动市场成长。根据全球健康观察站的资料，2015年非传染性疾病（NCD）占死亡人数的70.0%。主要的非传染性疾病是心血管疾病（CVD），占非传染性疾病死亡的45.0%；癌症，占非传染性疾病死亡的22.0%；慢性阻塞性肺病），占非传染性疾病死亡的10.0%；以及糖尿病。

製药市场亮点

  • 製药业占市场主导地位，2023 年收益占有率最大，为 85.0%。
  • 一级经济体将引领市场，到 2023 年市场占有率最大，达 60.5%。
  • 关键策略倡议包括新产品发布、收购/合併和联盟。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章医药市场变数、趋势和范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 医药市场分析工具
    • 波特的分析
    • PESTEL分析

第四章 医药市场：产品评估与趋势分析

  • 细分仪表板
  • 製药市场：2023 年和 2030 年按产品分类的波动分析
  • 製药
  • 其他医疗保健产业

第五章医药市场：经济预测与趋势分析

  • 细分仪表板
  • 医药市场：2023 年与 2030 年经济变迁分析
  • 1层级
  • 2层级
  • 3层级

第六章 医药市场：适应症估计与趋势分析

  • 细分仪表板
  • 医药市场：2023 年和 2030 年按适应症变化分析
  • 文明病
  • 癌症与自体免疫疾病
  • 感染疾病
  • 其他的

第七章 医药市场：区域估计与趋势分析

  • 2023 年及 2030 年按地区分類的製药市场占有率
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • Sanofi
    • Pfizer Inc.
    • AstraZeneca
    • GlaxoSmithKline
    • F. Hoffmann-La Roche Ltd.
    • GE Healthcare
    • Eli Lilly and Company
    • Medtronic
    • Abbott
    • Johnson and Johnson
简介目录
Product Code: GVR-2-68038-256-3

Pharmerging Market Growth & Trends:

The global pharmerging market size is expected to reach USD 2.08 trillion in 2030 and is projected to grow at a CAGR of 2.6% from 2024 to 2030. This market is expected to grow due to the increasing geriatric population, increasing disease burden of chronic disorders, and increasing healthcare expenditure.

According to the United Nations (UN), the number of people above the age of 60 years is estimated to be 901 million in 2015. The increasing geriatric population boosts the demand for better treatment options for chronic diseases such as hyperlipidemia, hypertension, cancer, dementia, congestive heart failure. According to a study conducted by Deloitte in 2011, the geriatric population accounts for almost 23.0-40.0% of the prescription drug market, and 40.0-50.0% of the OTC drug market. Another driving factor for the pharmerging market is increasing healthcare expenditure.

The increasing disease burden of chronic diseases in developing countries is boosting growth in the market. According to the Global Health Observatory data, in 2015, 70.0% of the deaths were due to non-communicable diseases (NCD). The major NCDs are cardiovascular diseases (CVD) which caused 45.0% of all NCD deaths, cancer which caused 22.0% of all NCD deaths and chronic obstructive pulmonary disease (COPD) which causes 10.0% of all NCD deaths, and diabetes which caused 4.0% of all NCD deaths.

Pharmerging Market Report Highlights:

  • The pharmaceutical product segment dominated the market and accounted for the largest revenue share of 85.0% in 2023.
  • The tier-1 economy led the market, accounting for the largest market share at 60.5% in 2023.
  • The key strategic initiatives include new product launches, acquisitions and mergers, and collaborations.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Pharmerging Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Billion)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Pharmerging Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Pharmerging Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Pharmerging Market: Product Movement Analysis, 2023 & 2030 (USD Billion)
  • 4.3. Pharmaceutical
    • 4.3.1. Pharmaceutical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
      • 4.3.1.1. Patented Prescription Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
      • 4.3.1.2. Generic Prescription Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
      • 4.3.1.3. OTC Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.4. Other Healthcare Verticals
    • 4.4.1. Other Healthcare Verticals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
      • 4.4.1.1. Medical Devices Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
      • 4.4.1.2. Clinical Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
      • 4.4.1.3. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. Pharmerging Market: Economy Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Pharmerging Market: Economy Movement Analysis, 2023 & 2030 (USD Billion)
  • 5.3. Tier-1
    • 5.3.1. Tier-1 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.4. Tier-2
    • 5.4.1. Tier-2 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.5. Tier-3
    • 5.5.1. Tier-3 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Pharmerging Market: Indication Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Pharmerging Market: Indication Movement Analysis, 2023 & 2030 (USD Billion)
  • 6.3. Lifestyle Diseases
    • 6.3.1. Lifestyle Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.4. Cancer & Autoimmune Diseases
    • 6.4.1. Cancer & Autoimmune Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.5. Infectious Diseases
    • 6.5.1. Infectious Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.6. Others
    • 6.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. Pharmerging Market: Regional Estimates & Trend Analysis

  • 7.1. Pharmerging Market Share, By Region, 2023 & 2030 (USD Billion)
  • 7.2. North America
    • 7.2.1. North America Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.3. Europe
    • 7.3.1. Europe Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.2. UK
      • 7.3.2.1. UK Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.4. France
      • 7.3.4.1. France Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.3. China
      • 7.4.3.1. China Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.4. India
      • 7.4.4.1. India Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.5. Australia
      • 7.4.5.1. Australia Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.6. South Korea
      • 7.4.6.1. South Korea Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5. Latin America
    • 7.5.1. Latin America Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Pharmerging Market Estimates and Forecasts, 2018 - 2030) (USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Sanofi
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Pfizer Inc.
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. AstraZeneca
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. GlaxoSmithKline
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. F. Hoffmann-La Roche Ltd.
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. GE Healthcare
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Eli Lilly and Company
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Medtronic
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Abbott
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Johnson and Johnson
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives